Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
Journal of Clinical Medicine · 23.11.2025 · 14 (23) · 8326
DOI: 10.3390/jcm14238326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.11.2025. Verfasst von Alberto Martínez-Castelao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin II receptor blockers (AIIRB); (2) sodium-glucose-transporter 2 (SGLT2) inhibitors; (3) glucagon-like peptide-1 receptor agonists (GLP-1 RA); and (4) an antagonist of type 1 endothelin receptor (ET1R) with proven efficacy to reduce albuminuria and proteinuria. (5) The mineralocorticoid receptor antagonist (MRA) finerenone has been tested in RCTs as a kidney protective agent. In our review, we summarize many of the principal trials that have generated evidence in this regard. Many novel agents—many of them proven not only for DM management but also for the treatment of obesity with or without DM or heart failure (HF)—are now in development and may be added to the five classical pillars: other non-steroidal MRA (balcinrenone); aldosterone synthase inhibitors (baxdrostat and vicadrostat); other GLP-1 RA (tirzepatide, survodutide, retatrutide, and cagrilintide); ET1 R antagonists, (zibotentan); and soluble guanylate cyclase activators (avenciguat). These new agents aim to slow disease progression further and reduce cardiovascular risk. Future strategies rely on integrated, patient-centered approaches and personalized therapy to curb renal disease and its related complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Bellvitge University Hospital, Hospitalet, 08907 Barcelona, Spain.
- GEENDIAB (Grupo Español de Estudio de la Nefropatía Diabética), Sociedad Española de Nefrología (S.E.N.), 39008 Santander, Spain.
- RED in REN-RICORS 2040, Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Servicio de Nefrología, INCLIVA, Universidad de Valencia, 46010 Valencia, Spain.
- GEENDIAB-S.E.N., 39008 Santander, Spain.
- RICORS2040 (RD24/004/0022), Instituto de Salud Carlos III, 28029 Madrid, Spain.
ORCID-Profile: Alberto Martínez-Castelao, José Luis Górriz, María José Soler, Juan F Navarro-González
Zitieren
APA
Martínez-Castelao, A., Górriz, J. L., Fernández-Fernández, B., Soler, M. J., & Navarro-González, J. F. (2025). Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Journal of Clinical Medicine, 14(23), 8326. https://doi.org/10.3390/jcm14238326
Vancouver
Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, Navarro-González JF. Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed. Journal of Clinical Medicine. 2025;14(23):8326. doi:10.3390/jcm14238326
BibTeX
@article{MartnezCastelao2025,
author = {Martínez-Castelao, Alberto and Górriz, José Luis and Fernández-Fernández, Beatriz and Soler, María José and Navarro-González, Juan F},
title = {Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {23},
pages = {8326},
doi = {10.3390/jcm14238326}
}
EUVIMED